Further studies have shown that in patients with BRAF-mutated metastatic melanoma, the combination of the BRAF inhibitor Dabrafenib and the MEK inhibitor Trametinib may be an effective therapeutic modality, demonstrating impressive remission rates and survival benefits (22). Here, MAP2K7 is linked to metastatic melanoma.